: iStockAnalyst.com Symbols Feed

Which Pharma Pipelines Rank Best?

Thu, 17 Sep 2009 13:42:30 GMT

For the majority of pharmaceutical companies, strong pipelines should offset the approaching patent cliff.[More...]

Small-Cap Stocks Battling Brain Cancer

Tue, 08 Sep 2009 00:02:23 GMT

Each year nearly 20,000 people in the U.S. are diagnosed with primary brain cancers (with a similar number in Europe), according to NCI/NIH statistics, with Schering-Plough's (NYSE:SGP) Temodar (temozolomide or TMZ is classified as a DNA-methylating chemotherapy drug) given to nearly every patient with a diagnosis of GBM (the most common and aggressive form of brain cancer).[More...]

FDA Calendar Updates: Anadys, Merck, Schering-Plough

Fri, 31 Jul 2009 01:05:36 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 289 entries as of 7/30/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete respo (...)[More...]

An Outsider’s Perspective On High Frequency Trading

Wed, 29 Jul 2009 17:18:00 GMT

I think it would be an understatement to say that there is a lot of confusion in the mainstream press and in the blogosphere regarding high frequency trading (HFT). For many of us, it is only in the last few weeks that we have started to add the words “co-location,” “flash trading,” and “predatory algorithms” into our lexicon. Fortunately for HFT novices like myself, blogosphere luminaries such as Karl Denninger of The Market Ticker and Tyler Durden of [More...]

FDA Calendar Updates: BVX, HEB, HGSI, ONXX, SGP, ARDM, CBRX, MDT, Takeda

Thu, 23 Jul 2009 15:48:00 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 273 entries as of 7/22/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete respo (...)[More...]

FDA Extreme Trades: 16 Stocks Under $5

Sat, 27 Jun 2009 20:50:19 GMT

Below are FDA extreme trades among 16 companies with stock prices under $5 from the BioMedReports.com FDA Calendar (database includes 225 entries as of 6/27/09) which have pending FDA decisions for either new drug products, biological agents, medical devices, or diagnostic tests that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of (...)[More...]

How To Make 50% With Next To No Risk

Fri, 19 Jun 2009 14:34:19 GMT

Ten years ago, hopeless investors chased Internet stocks hoping to cherry-pick the next takeout target, searching for an overnight triple-digit gain. They did it again with biotech in 2000 and again with oil stocks in 2007. They all lost money. You see, most folks do the exact opposite of what they should be doing when it comes to speculating in mergers... With thousands of possible acquisition targets, trying to guess the next takeout is a sucker's bet. And novice traders plow money into one buyout candidate after another, only to suffer a handful of 30%... 40%... or 50% losses when no suitors come knocking. These folks don't know the real secret behind picking up free money from mergers: Big profits are banked AFTER the buyout announcement. The strategy – known as "merger arbitrage" – is so simple and lucrative, an entire[More...]

Value Investing

Wed, 10 Jun 2009 13:56:00 GMT

All companies listed below met The Applied Finance Group's (AFG's) Buy screen criteria and are in the bottom half of their sector in Market Value/Invested Capital (MV/IC), which by definition qualifies the companies as part of the AFG Value Universe. When identifying buy ideas, AFG looks for companies with the most valuation upside compared to their sector peers, above sector median expected Economic Margin change, and a management quality score that reflects a management team following a wealth creating strategy. 9 Value Companies To Watch A brief description of AFG's buy criteria variables: AFG's Valuation[More...]

BioMedReports.com Extreme Trades: ACAD, ANPI, BSTC, RPRX, SNTS

Tue, 09 Jun 2009 19:20:33 GMT

Below are four companies with market caps under $200 million (all financial data current as of 6/9/09 during intraday trading) which have pending FDA decisions and/or clinical trial results that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in Extreme FDA and Clinical Trial Calendar Trades, which are highlighted (...)[More...]

Pharmaceuticals & Biotech - Industry Outlook

Tue, 09 Jun 2009 12:05:35 GMT

The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x, including: Pfizer (PFE, 7.5x), Eli Lilly (LLY,[More...]

Business Highlights

Mon, 02 Nov 2009 22:47:00 GMT

3 strong economic reports lift recovery hopes
WASHINGTON (AP) - Hopes for the fledgling economic recovery got a boost Monday from better-than-expected news on manufacturing, construction and contracts to buy homes.
Construction spending rose a bigger-than-expected a 0.8 percent in September, while the National Association of Realtors said the volume of signed contracts to buy previously occupied homes rose 6.1 percent in September to a reading of 110.1.

: iStockAnalyst.com Symbols Feed

Which Pharma Pipelines Rank Best?

Small-Cap Stocks Battling Brain Cancer

FDA Calendar Updates: Anadys, Merck, Schering-Plough

An Outsider’s Perspective On High Frequency Trading

FDA Calendar Updates: BVX, HEB, HGSI, ONXX, SGP, ARDM, CBRX, MDT, Takeda

FDA Extreme Trades: 16 Stocks Under $5

How To Make 50% With Next To No Risk

Value Investing

BioMedReports.com Extreme Trades: ACAD, ANPI, BSTC, RPRX, SNTS

Pharmaceuticals & Biotech - Industry Outlook

Business Highlights

Schering-Plough Shares Hit Premerger Bump -- Fails Expectations, but Merck Deal Encouraging

Schering-Plough Shares Hit Premerger Bump

Bristol-Myers posts higher 3Q sales, lower profit

Earnings Preview: Bristol-Myers 3Q earnings report

SGP Pays B1.75bn for Chevron Unit in China

Pa. Isn't Expected to Lose Jobs When Pfizer Acquires Wyeth

Pa. Isn't Expected to Lose Jobs When Pfizer Acquires Wyeth

Abbott to buy Solvay division for $6.6B

Business Highlights

Merck and Schering-Plough to Complete Merger Today

Ligand to Acquire Metabasis for Cash and Contingent Value Rights

RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on OLN, LXK, SGP, MMM, LYG and STSI

Fitch: Credit Quality Stable for Global Pharma Sector With Increase of New Drug Approvals in 2Q'09

Schering-Plough Announces Two European Filings

SCHERING-PLOUGH ANNOUNCES FDA APPROVAL OF SAPHRIS(R) (asenapine): for acute treatment of schizophrenia in adults and manic or mixed episodes of bipolar I disorder with or without psychotic features in adults

Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults

Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R)

BenchmarkJournal.Com Free Analyst Review for PGH, JEC, PL, SGP, UPS and WCC

Photos: New CLARITIN(R) Eye Relieves Itchy Eyes For Up To 12 Hours

Form 4 MCGRATH EUGENE R For: Nov 03 (10K)

Form 4 Colligan Thomas J For: Nov 03 (10K)

Form 4 PEREZ ANTONIO M For: Nov 03 (10K)

Form 4 WEINBACH ARTHUR F For: Nov 03 (10K)

Form 4 Merck & Co. Inc. For: Nov 03 Filed by: STAHL JACK L (10K)

Form 4 SAUNDERS BRENT L For: Nov 03 (10K)

Form 4 Merck & Co. Inc. For: Nov 03 Filed by: TURNER KATHRYN C (10K)

Form 4 SABATINO THOMAS J JR For: Nov 03 (10K)

Form 4 VAN OORDT ROBERT FW For: Nov 03 (10K)

Form 4 Queisser Lori A. For: Nov 03 (10K)